Background
The CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1) trial was a multicenter randomized controlled trial assessing convalescent plasma in hospitalized COVID-19 patients. Though stopped early due to the lack of treatment benefit, the cost-effectiveness of convalescent plasma provides insight into its potential as an alternative treatment option in resource constrained settings.
Methods
Individual patient data on health outcomes and healthcare resource utilization from the CONCOR-1 trial were used to conduct the analysis from the Canadian public payer’s perspective with a time horizon of 30 days post-randomization. Baseline and 30-day EQ-5D-5L was measured to calculate quality-adjusted survival. All costs are presented in 2021 Canadian dollars. The base case assessed the EQ-5D-5L scores of patients reporting at both timepoints, and a utility score of 0 was assigned for patients who died within 30 days. Costs for all patients enrolled in the study were used. The sensitivity analysis utilizes EQ-5D-5L scores from the same population but only uses the costs from this population.
Results
940 patients were randomized: 627 received CCP and 313 received standard care. The total costs were $28,716 (standard deviation, $25,380) and $24,258 ($22,939) for the convalescent plasma and standard care arms respectively. EQ-5D-5L scores were 0.61 both arms (p = 0.85) at baseline. At 30 days, EQ-5D-5L scores were 0.63 and 0.64 for patients in the convalescent plasma and standard care arms respectively (p = 0.46). The incremental cost was $4,458 and incremental quality-adjusted life day was − 0.078.
Conclusion
These results indicate that convalescent plasma was less effective and more costly than standard care in treating hospitalized patients with COVID-19. The sensitivity analysis yielded similar results to the base case analysis.